ARCHIVES

More Cost-Effective To Use Cetuximab In Patients With Wild-Type KRAS Gene

This article is from The Cancer Letter archive.

Vol. 32 No. 8 | August 28, 2009

Download PDF Visit The Full Archive

Related Articles

HCFA Abadons Plan To Cut Cancer Drug Payments.

September 15, 2000

UCLA, NYU, Ohio States Must Wait Longer For Comprehensive Status

November 28, 1975

Phase II Study Finds Dasatinib May Overcome ALL Resistance

May 25, 2007

Avon 1995 Grant Application Available

December 2, 1994

Funding Opportunities

January 10, 2003

NCI Faced Pressure From Congress, HHS, White On Mammography Statement

April 11, 1997